Defining genomic, transcriptomic, proteomic, epigenetic, and phenotypic biomarkers with prognostic capability in male breast cancer: a systematic review

Subarnarekha Chatterji; Emma Krzoska; Christopher W  Thoroughgood; John  Saganty; Peng Liu; Beatrix Elsberger; Rasha Abu Eid; Valerie Speirs

doi:10.1016/S1470-2045(22)00633-7

Defining genomic, transcriptomic, proteomic, epigenetic, and phenotypic biomarkers with prognostic capability in male breast cancer: a systematic review

Subarnarekha Chatterji, Emma Krzoska, Christopher W Thoroughgood, John Saganty, Peng Liu, Beatrix Elsberger, Rasha Abu Eid, Valerie Speirs^* (Corresponding Author)

^*Corresponding author for this work

Research output: Contribution to journal › Review article › peer-review

13 Citations (Scopus)

7 Downloads (Pure)

Abstract

While similar phenotypically, there is evidence that male and female breast cancer differ in their molecular landscapes. In this systematic review, we consolidated all existing prognostic biomarker data in male breast cancer, spanning genetics, transcriptomics, proteomics, and epigenetics as well as phenotypic features of prognostic value from articles published in a 29-year period (1992 – 2021). We identified knowledge gaps in the existing literature, discussed limitations of included studies, and outlined potential approaches for translational biomarker discovery and validation in male breast cancer. We also recognised STC2, DDX3, and DACH1 as underexploited markers of male-specific prognostic value in breast cancer. Finally, beyond describing the cumulative knowledge on the extensively researched markers ERα, PR, HER2, AR, and BRCA2, we highlighted ATM, CCND1, FGFR2, GATA3, HIF1α, MDM2, p53 and c-Myc as well-studied predictors of poor survival, that also aligned with several hallmarks of cancer

Original language	English
Pages (from-to)	e74-e85
Number of pages	12
Journal	The Lancet Oncology
Volume	24
Issue number	2
Early online date	30 Jan 2023
DOIs	https://doi.org/10.1016/S1470-2045(22)00633-7
Publication status	Published - 1 Feb 2023

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/S1470-2045(22)00633-7

Chatterji_etal_LO_Defining_Genomic_Transcriptomic_AAM
© 2023. This manuscript version is made available under the CC-BY-NC-ND 4.0 license https://creativecommons.org/licenses/by-nc-nd/4.0/
Accepted author manuscript, 2.58 MBLicence: CC BY-NC-ND

Cite this

Defining genomic, transcriptomic, proteomic, epigenetic, and phenotypic biomarkers with prognostic capability in male breast cancer: a systematic review. / Chatterji, Subarnarekha; Krzoska, Emma; Thoroughgood, Christopher W et al.
In: The Lancet Oncology, Vol. 24, No. 2, 01.02.2023, p. e74-e85.

Research output: Contribution to journal › Review article › peer-review

@article{fe13f8c71ff74799b295cb0817d0d799,

title = "Defining genomic, transcriptomic, proteomic, epigenetic, and phenotypic biomarkers with prognostic capability in male breast cancer: a systematic review",

abstract = "While similar phenotypically, there is evidence that male and female breast cancer differ in their molecular landscapes. In this systematic review, we consolidated all existing prognostic biomarker data in male breast cancer, spanning genetics, transcriptomics, proteomics, and epigenetics as well as phenotypic features of prognostic value from articles published in a 29-year period (1992 – 2021). We identified knowledge gaps in the existing literature, discussed limitations of included studies, and outlined potential approaches for translational biomarker discovery and validation in male breast cancer. We also recognised STC2, DDX3, and DACH1 as underexploited markers of male-specific prognostic value in breast cancer. Finally, beyond describing the cumulative knowledge on the extensively researched markers ERα, PR, HER2, AR, and BRCA2, we highlighted ATM, CCND1, FGFR2, GATA3, HIF1α, MDM2, p53 and c-Myc as well-studied predictors of poor survival, that also aligned with several hallmarks of cancer",

author = "Subarnarekha Chatterji and Emma Krzoska and Thoroughgood, {Christopher W} and John Saganty and Peng Liu and Beatrix Elsberger and {Abu Eid}, Rasha and Valerie Speirs",

year = "2023",

month = feb,

day = "1",

doi = "10.1016/S1470-2045(22)00633-7",

language = "English",

volume = "24",

pages = "e74--e85",

journal = "The Lancet Oncology",

issn = "1470-2045",

publisher = "Lancet Publishing Group",

number = "2",

}

TY - JOUR

T1 - Defining genomic, transcriptomic, proteomic, epigenetic, and phenotypic biomarkers with prognostic capability in male breast cancer

T2 - a systematic review

AU - Chatterji, Subarnarekha

AU - Krzoska, Emma

AU - Thoroughgood, Christopher W

AU - Saganty, John

AU - Liu, Peng

AU - Elsberger, Beatrix

AU - Abu Eid, Rasha

AU - Speirs, Valerie

PY - 2023/2/1

Y1 - 2023/2/1

N2 - While similar phenotypically, there is evidence that male and female breast cancer differ in their molecular landscapes. In this systematic review, we consolidated all existing prognostic biomarker data in male breast cancer, spanning genetics, transcriptomics, proteomics, and epigenetics as well as phenotypic features of prognostic value from articles published in a 29-year period (1992 – 2021). We identified knowledge gaps in the existing literature, discussed limitations of included studies, and outlined potential approaches for translational biomarker discovery and validation in male breast cancer. We also recognised STC2, DDX3, and DACH1 as underexploited markers of male-specific prognostic value in breast cancer. Finally, beyond describing the cumulative knowledge on the extensively researched markers ERα, PR, HER2, AR, and BRCA2, we highlighted ATM, CCND1, FGFR2, GATA3, HIF1α, MDM2, p53 and c-Myc as well-studied predictors of poor survival, that also aligned with several hallmarks of cancer

AB - While similar phenotypically, there is evidence that male and female breast cancer differ in their molecular landscapes. In this systematic review, we consolidated all existing prognostic biomarker data in male breast cancer, spanning genetics, transcriptomics, proteomics, and epigenetics as well as phenotypic features of prognostic value from articles published in a 29-year period (1992 – 2021). We identified knowledge gaps in the existing literature, discussed limitations of included studies, and outlined potential approaches for translational biomarker discovery and validation in male breast cancer. We also recognised STC2, DDX3, and DACH1 as underexploited markers of male-specific prognostic value in breast cancer. Finally, beyond describing the cumulative knowledge on the extensively researched markers ERα, PR, HER2, AR, and BRCA2, we highlighted ATM, CCND1, FGFR2, GATA3, HIF1α, MDM2, p53 and c-Myc as well-studied predictors of poor survival, that also aligned with several hallmarks of cancer

U2 - 10.1016/S1470-2045(22)00633-7

DO - 10.1016/S1470-2045(22)00633-7

M3 - Review article

C2 - 36725152

SN - 1470-2045

VL - 24

SP - e74-e85

JO - The Lancet Oncology

JF - The Lancet Oncology

IS - 2

ER -

Defining genomic, transcriptomic, proteomic, epigenetic, and phenotypic biomarkers with prognostic capability in male breast cancer: a systematic review

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this